Unknown

Dataset Information

0

Adjuvant anti-PD-1 therapy improves melanoma-specific survival in stage IIIC-IV melanoma patients with high tumor mutation burden and BRAF V600 mutation

ABSTRACT:

SUBMITTER: Forschner J 

PROVIDER: S-EPMC12378509 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma.
| S-EPMC11954497 | biostudies-literature
Unknown Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.
| S-EPMC4289407 | biostudies-literature
Unknown High BRAF V600 Mutation Level Associated with Worse Outcome in Metastatic Melanoma Patients Receiving BRAF and MEK Inhibitors.
| S-EPMC11558860 | biostudies-literature
Unknown Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
| S-EPMC3549295 | biostudies-literature
Unknown BRAF V600 Mutation and BRAF Kinase Inhibitors in Conjunction With Stereotactic Radiosurgery for Intracranial Melanoma Metastases: A Multicenter Retrospective Study.
| S-EPMC6505443 | biostudies-literature
Unknown A Rare Complex BRAF Mutation Involving Codon V600 and K601 in Primary Cutaneous Melanoma: Case Report.
| S-EPMC7367153 | biostudies-literature
Unknown Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study.
| S-EPMC10641479 | biostudies-literature
Unknown Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma.
| S-EPMC3421463 | biostudies-literature
Unknown Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
| S-EPMC3724515 | biostudies-literature
Unknown Switching PD-1 to BRAF + MEK inhibition improves recurrence-free survival in patients receiving a second course of adjuvant melanoma therapy.
| S-EPMC12553123 | biostudies-literature